3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Breast
1
Conditions
Fasting
9
Prostatic Neoplasms
3
Breast Neoplasms
3
Intermittent Fasting
2
Colorectal Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Sarcoma
1
Polycystic Ovary Syndrome
1
Ovarian Neoplasms
1
Neoplasms
1
Lymphoma
1
Liposarcoma
1
Infertility
1
Histiocytoma, Malignant Fibrous
1
Glioma
1
Fibrosis
1
Fasting in Malignant Solid Tumors
1
Esophageal Neoplasms
1
Dermatofibrosarcoma
1
Childhood Cancer Survivors
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Paclitaxel
326
Carboplatin
318
Bevacizumab
167
Gemcitabine
106
pembrolizumab
101
liposomal doxorubicin
100
Cyclophosphamide
96
Topotecan
93
Cisplatin
89
olaparib
86
niraparib
60
Docetaxel
56
Taxes
52
Doxorubicin
50
Drug Therapy
42
fludarabine
40
Filgrastim
39
Nivolumab
37
Etoposide
32
Specimen Handling
31
Magnetic Resonance Spectroscopy
29
Immunoglobulin G
27
Disulfides
27
Peripheral Blood Stem Cell Transplantation
26
Albumin-Bound Paclitaxel
25
durvalumab
24
aldesleukin
24
Hyperthermic Intraperitoneal Chemotherapy
24
Oxaliplatin
23
Biopsy
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Ovarian Neoplasms
×
Angptl4 protein, mouse
×
Clear all
NCT03162289
2022-12-13
FIT2
Charite University, Berlin, Germany
Phase NA
Unknown
150 enrolled